NCT06944704

Evaluation of Efficacy, Safety and Molecular Mechanism of Pentoxifylline Supplementation in Patients With Hepatic and Obstructive Jaundice

Clinical Study Evaluating Efficacy, Safety and Molecular Mechanism of Pentoxifylline Supplementation in Patients With Hepatic and Post Hepatic Jaundice

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 43 (actual)
• Sponsor: Tanta University · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Investigating the efficacy, safety, and molecular mechanism of Pentoxifylline supplementation in improving elevated direct bilirubin level and liver function tests in patients with hepatic and post-hepatic jaundice

Conditions

• Hepatobiliary Disorders

Interventions

Type	Name	Description
DRUG	Pentoxifylline	Patients will receive oral Pentoxifylline 400 mg twice daily in addition to supportive treatment, for 3 months.

Timeline

• Start date: 2024-04-03
• Primary completion: 2025-03-19
• Completion: 2025-03-19
• First posted: 2025-04-25
• Last updated: 2025-07-30

Locations

1 site across 1 country: Egypt